S. Mueller, O. Weber, C. Duc
Jan 1, 2001
Citations
2
Influential Citations
41
Citations
Quality indicators
Journal
Epilepsia
Abstract
Summary: Purpose: Vigabatrin (VGB) is a new antiepileptic drug that increases the human brain γ‐aminobutyric acid (GABA) level by irreversibly inhibiting GABA transaminase. Although some patients respond to VGB with a significant seizure reduction, others do not. The aim of this study was to identify possible responders before or in an early phase of VGB treatment by measuring the GABA and homocarnosine contaminated with macromolecules/creatine and phosphocreatine ratio (GABA+/Cr) signal by means of proton‐nuclear magnetic resonance (1H NMR) spectroscopy.